Rinri Therapeutics is at the forefront of developing innovative cell therapies aimed at treating sensorineural hearing loss. The company focuses on creating first-in-class approaches that seek to transform patient experiences with hearing loss. Their lead product, Rincell-1, is designed for adults suffering from severe-to-profound age-related hearing loss or Auditory Neuropathy, and is expected to enter clinical trials in 2025. Rinri emphasizes the importance of patient engagement, working closely with individuals who have experienced hearing loss to inform their development process and ensure that their therapies address real-world needs and limitations of existing treatments.

In addition to patient involvement, Rinri Therapeutics collaborates with clinicians and key opinion leaders in the field of hearing health to guide their research and clinical strategies. This partnership aims to integrate novel therapeutics into standard clinical practices, ensuring that ENT doctors and audiologists play a crucial role in the management of hearing loss. By fostering these collaborations, Rinri is committed to improving outcomes for patients and advancing the understanding of hearing health, ultimately striving to restore hearing and enhance the quality of life for those affected by hearing loss.

United Kingdom

Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.

Rinri Therapeutics

Company Details